371 related articles for article (PubMed ID: 25792249)
1. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
[TBL] [Abstract][Full Text] [Related]
2. Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
Perri T; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Fertil Steril; 2021 Aug; 116(2):538-545. PubMed ID: 33823990
[TBL] [Abstract][Full Text] [Related]
3. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gronwald J; Glass K; Rosen B; Karlan B; Tung N; Neuhausen SL; Moller P; Ainsworth P; Sun P; Narod SA; Lubinski J; Kotsopoulos J;
Fertil Steril; 2016 Mar; 105(3):781-785. PubMed ID: 26698676
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
7. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie O; Chetrit A; Novikov I; Sadetzki S;
Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
[TBL] [Abstract][Full Text] [Related]
8. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
Shapira M; Raanani H; Feldman B; Srebnik N; Dereck-Haim S; Manela D; Brenghausen M; Geva-Lerner L; Friedman E; Levi-Lahad E; Goldberg D; Perri T; Eldar-Geva T; Meirow D
Fertil Steril; 2015 Nov; 104(5):1162-7. PubMed ID: 26335130
[TBL] [Abstract][Full Text] [Related]
9. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
10. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Laitman Y; Michaelson-Cohen R; Levi E; Chen-Shtoyerman R; Reish O; Josefsberg Ben-Yehoshua S; Bernstein-Molho R; Keinan-Boker L; Rosengarten O; Silverman BG; Perri T; Korach J; Mor P; Ephrat Ben-Baruch N; Levy Lahad E; Friedman E;
Cancer; 2019 Mar; 125(5):698-703. PubMed ID: 30489631
[TBL] [Abstract][Full Text] [Related]
11. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
12. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
13. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM
Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
15. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
16. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
[TBL] [Abstract][Full Text] [Related]
17. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
18. Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
Johnson L; Sammel MD; Domchek S; Schanne A; Prewitt M; Gracia C
Fertil Steril; 2017 May; 107(5):1256-1265.e6. PubMed ID: 28476184
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
